0
0Researchers have demonstrated that combining an HIV vaccine with an intravaginal ring delivering the drug SAMT-247 significantly reduces the risk of virus acquisition in macaques. This dual-intervention strategy achieved an 82.8% reduction in infection risk, outperforming the results of the vaccine or the drug-delivery device used in isolation. The study reveals that the continuous release of the microbicide strengthens mucosal immunity by expanding specific anti-inflammatory and regulatory cell populations. Key protective factors identified include enhanced natural killer cell activity and V2-specific antibody responses that help maintain the integrity of the mucosal barrier. These findings suggest that sustained local drug delivery can synergize with immunization to provide a more durable defense against transmission. Ultimately, this approach offers a promising framework for developing low-cost, long-acting biomedical tools to combat the HIV epidemic.
References:
Rahman M A, Woode E K, Moss J A, et al. Sustained mucosal delivery of SAMT-247 via an intravaginal ring reduces the risk of SIVmac251 acquisition in vaccinated macaques[J]. Cell Reports Medicine, 2026.
